FTC Hits Edwards Lifesciences, Genesis MedTech with $12M HSR Penalties
FTC fined Edwards Lifesciences $10M and Genesis MedTech $2M for structuring deals to evade HSR filings.
Why it matters: Merger compliance teams face heightened scrutiny as deliberate deal splitting below HSR thresholds can trigger costly FTC penalties and legal actions.
- FTC fined Edwards Lifesciences $10 million and Genesis MedTech $2 million for HSR violations.
- Edwards’ July 2024 JC Medical deal was valued at $115M, just under the $119.5M HSR filing threshold.
- A $25 million separate investment in Genesis MedTech aimed to evade merger notification requirements.
- FTC sued and blocked Edwards’ 2024 proposed acquisition of JenaValve Technology, with a 2026 preliminary injunction.
On July 13, 2026, the Federal Trade Commission (FTC) imposed $12 million in penalties on Edwards Lifesciences Corp. and Genesis MedTech Group Limited for violating the Hart-Scott-Rodino (HSR) Act.
Edwards received a $10 million fine; Genesis was charged $2 million. The penalties relate to Edwards’ July 2024 acquisition of JC Medical, valued at $115 million—just below the $119.5 million HSR filing threshold. The companies made an additional $25 million investment in Genesis MedTech, which the FTC said was designed to circumvent merger notification and waiting period requirements.
HSR rules mandate pre-merger notifications to the FTC and Department of Justice to allow antitrust review of significant transactions. FTC Chairman Andrew N. Ferguson stated that companies attempting to bypass lawful FTC review face serious consequences.
Separately, Edwards sought to acquire JC Medical’s competitor, JenaValve Technology Inc., in July 2024. The FTC sued to block this deal, raising antitrust concerns. A federal court issued a preliminary injunction in January 2026, temporarily halting the acquisition.
Under the settlement, Edwards is required to notify the FTC in advance of acquiring any interest in companies involved with transcatheter aortic valve replacement (TAVR) devices addressing aortic regurgitation in the U.S. The company must also implement a robust antitrust compliance program to prevent future violations.
This enforcement action signals increased FTC focus on merger compliance, cautioning legal teams to critically evaluate deal structuring near HSR thresholds to avoid financial penalties and litigation risks.
By the numbers:
- $12M total penalties—$10M Edwards Lifesciences, $2M Genesis MedTech
- $119.5M—HSR Act filing threshold in effect during July 2024
- $115M—value of Edwards’ JC Medical acquisition just below filing threshold
Yes, but: While the FTC strongly enforces HSR compliance, companies can challenge penalties and injunctions in court, which may delay final outcomes.
What's next: Further FTC enforcement of structured deals near HSR thresholds is expected, with companies under closer scrutiny for merger compliance.